Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis
出版年份 2021 全文链接
标题
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis
作者
关键词
Pancreatic cancer, FOLFIRINOX, Gemcitabine/nab-paclitaxel, First-line treatment, Real-world, Propensity score
出版物
EUROPEAN JOURNAL OF CANCER
Volume 151, Issue -, Pages 3-13
出版商
Elsevier BV
发表日期
2021-05-02
DOI
10.1016/j.ejca.2021.03.040
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Impact of New Chemotherapy Regimens on the Treatment Landscape and Survival of Locally Advanced and Metastatic Pancreatic Cancer Patients
- (2020) Markus Kieler et al. Journal of Clinical Medicine
- FOLFIRINOX vs gemcitabine/nab-paclitaxel for treatment of metastatic pancreatic cancer: Single-center cohort study
- (2020) In Rae Cho et al. World Journal of Gastrointestinal Oncology
- Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study
- (2020) Philip A Philip et al. Lancet Gastroenterology & Hepatology
- European cancer mortality predictions for the year 2020 with a focus on prostate cancer
- (2020) G. Carioli et al. ANNALS OF ONCOLOGY
- SWOG S1505: Results of perioperative chemotherapy (peri-op CTx) with mfolfirinox versus gemcitabine/nab-paclitaxel (Gem/nabP) for resectable pancreatic ductal adenocarcinoma (PDA).
- (2020) Davendra Sohal et al. JOURNAL OF CLINICAL ONCOLOGY
- Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma
- (2020) Giampaolo Perri et al. JAMA Surgery
- Guidelines Insights: Pancreatic Adenocarcinoma, Version 1.2019
- (2019) Margaret A. Tempero et al. Journal of the National Comprehensive Cancer Network
- Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis
- (2019) Florian Moik et al. Scientific Reports
- Results from the prospective German TPK clinical cohort study: Treatment algorithms and survival of 1,174 patients with locally advanced, inoperable or metastatic pancreatic ductal adenocarcinoma
- (2018) Susanna Hegewisch-Becker et al. INTERNATIONAL JOURNAL OF CANCER
- Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis
- (2018) Jihoon Kang et al. INVESTIGATIONAL NEW DRUGS
- Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States
- (2018) Sunnie Kim et al. ADVANCES IN THERAPY
- FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
- (2018) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
- PANCREOX: A Randomized Phase III Study of Fluorouracil/Leucovorin With or Without Oxaliplatin for Second-Line Advanced Pancreatic Cancer in Patients Who Have Received Gemcitabine-Based Chemotherapy
- (2016) Sharlene Gill et al. JOURNAL OF CLINICAL ONCOLOGY
- Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial
- (2016) Andrea Wang-Gillam et al. LANCET
- Epidemiology of pancreatic cancer
- (2016) Milena Ilic et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) M. Ducreux et al. ANNALS OF ONCOLOGY
- Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
- (2015) Peter C. Austin et al. STATISTICS IN MEDICINE
- Second-Line Oxaliplatin, Folinic Acid, and Fluorouracil Versus Folinic Acid and Fluorouracil Alone for Gemcitabine-Refractory Pancreatic Cancer: Outcomes From the CONKO-003 Trial
- (2014) Helmut Oettle et al. JOURNAL OF CLINICAL ONCOLOGY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
- (2011) Thierry Conroy et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started